Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

Abstract

IMPORTANCE Glioblastoma is the most devastating primary malignancy of the central nervous system in adults. Most patients die within 1 to 2 years of diagnosis. Tumor-treating fields (TTFields) are a locoregionally delivered antimitotic treatment that interferes with cell division and organelle assembly. OBJECTIVE To evaluate the efficacy and safety of… (More)
DOI: 10.1001/jama.2015.16669

Topics

4 Figures and Tables

Cite this paper

@article{Stupp2015MaintenanceTW, title={Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.}, author={Roger Stupp and Sophie Taillibert and A A Kanner and Santosh Kesari and David M. Steinberg and Steven A. Toms and Lynne Taylor and Frank Lieberman and Antonio Silvani and Karen L. Fink and Gene H. Barnett and Jay-Jiguang Zhu and John W. Henson and Herbert H. Engelhard and Thomas C. Chen and David Tran and Jan Sroubek and Nam Tran and Andreas F. Hottinger and Joseph C. Landolfi and Rajiv S. Desai and Manuela Caroli and Yvonne Kew and J{\'e}r{\^o}me Honnorat and Ahmed Idbaih and Eilon D. Kirson and Uri Weinberg and Yoram Palti and Monika E Hegi and Zvi Ram}, journal={JAMA}, year={2015}, volume={314 23}, pages={2535-43} }